The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study

Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597[sup.®] (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nutrients 2021-06, Vol.13 (6)
Hauptverfasser: Déchelotte, Pierre, Breton, Jonathan, Trotin-Picolo, Clémentine, Grube, Barbara, Erlenbeck, Constantin, Bothe, Gordana, Fetissov, Sergueï O, Lambert, Grégory
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page
container_title Nutrients
container_volume 13
creator Déchelotte, Pierre
Breton, Jonathan
Trotin-Picolo, Clémentine
Grube, Barbara
Erlenbeck, Constantin
Bothe, Gordana
Fetissov, Sergueï O
Lambert, Grégory
description Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597[sup.®] (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH, reduced weight gain and adiposity in rodent models of obesity. Methods: To investigate the clinical efficacy of HA, 236 overweight subjects were included, after written informed consent, in a 12-week prospective, double-blind, randomized study. All subjects received standardized counselling for a −20% hypocaloric diet and were asked to maintain their usual physical activity. Subjects of the HA group received two capsules per day providing 100 billion bacteria per day and subjects in the Placebo (P) group received two placebo capsules. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. Intention-to-treat statistical analysis was performed using exact-Fischer, Mann-Whitney and paired-Wilcoxon tests as appropriate. Results: In the HA group, significantly more subjects (+33%) met the primary endpoint than in the P group (54.9 vs. 41.4%, p = 0.048). In the HA group, an increased feeling of fullness (p = 0.009) and a greater loss of hip circumference (p < 0.001) at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower (p < 0.05) in the HA compared to P group. Clinical and biological tolerance was good in both groups. Conclusions: A 12-week treatment with the probiotic strain H. alvei HA4597[sup.®] significantly improves weight loss, feeling of fullness and reduction of hip circumference in overweight subjects following moderate hypocaloric diet. These data support the use of H. alvei HA4597[sup.®] in the global management of excess weight.
doi_str_mv 10.3390/nu13061902
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A765866944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A765866944</galeid><sourcerecordid>A765866944</sourcerecordid><originalsourceid>FETCH-LOGICAL-g674-9f7a8626a8c16ebdb3fa6f7a71cb2eab70b05589ef0f0c1dac8e1448243cb0bb3</originalsourceid><addsrcrecordid>eNptUNtKAzEQXURB0b74BQFfuzV7abLrW62XFlpabMEHkZLLbBtJk7LJVvSj_Ag_wG8ypT70wZlhZjicMzNMFF0muJNlJb42TZJhkpQ4PYrOUkzTmJA8Oz7oT6OWc294ZxRTkp1FP_MVoGltubJeCTTzNVMGDQcdxPQW1PUQDXp5t6Qvrtl0vr9e0XC9qe0WHHoGtVx5NLLOoSCZbKF-30Ozhr-B8A41RkKNxjZk5gENPjZWMG3rsOhOgb9Bvd1qW8Uh-tYI2Pg2Gjc6XALGB-kTM9Ku1SfINrqzDdcQ32plJJpqJoDbncrXVmuQ4fRGflxEJxXTDlp_9TyaP9zP-4N4NHkc9nujeEloHpcVZQVJCStEQoBLnlWMBIwmgqfAOMUcd7tFCRWusEgkEwUkeV6keSY45jw7j672Y5dMw0KZyoa_ibVyYtGjpFsQUuZ5YHX-YQWXsFbCGqhUwA8Ev4hFjdk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Déchelotte, Pierre ; Breton, Jonathan ; Trotin-Picolo, Clémentine ; Grube, Barbara ; Erlenbeck, Constantin ; Bothe, Gordana ; Fetissov, Sergueï O ; Lambert, Grégory</creator><creatorcontrib>Déchelotte, Pierre ; Breton, Jonathan ; Trotin-Picolo, Clémentine ; Grube, Barbara ; Erlenbeck, Constantin ; Bothe, Gordana ; Fetissov, Sergueï O ; Lambert, Grégory</creatorcontrib><description>Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597[sup.®] (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH, reduced weight gain and adiposity in rodent models of obesity. Methods: To investigate the clinical efficacy of HA, 236 overweight subjects were included, after written informed consent, in a 12-week prospective, double-blind, randomized study. All subjects received standardized counselling for a −20% hypocaloric diet and were asked to maintain their usual physical activity. Subjects of the HA group received two capsules per day providing 100 billion bacteria per day and subjects in the Placebo (P) group received two placebo capsules. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. Intention-to-treat statistical analysis was performed using exact-Fischer, Mann-Whitney and paired-Wilcoxon tests as appropriate. Results: In the HA group, significantly more subjects (+33%) met the primary endpoint than in the P group (54.9 vs. 41.4%, p = 0.048). In the HA group, an increased feeling of fullness (p = 0.009) and a greater loss of hip circumference (p &lt; 0.001) at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower (p &lt; 0.05) in the HA compared to P group. Clinical and biological tolerance was good in both groups. Conclusions: A 12-week treatment with the probiotic strain H. alvei HA4597[sup.®] significantly improves weight loss, feeling of fullness and reduction of hip circumference in overweight subjects following moderate hypocaloric diet. These data support the use of H. alvei HA4597[sup.®] in the global management of excess weight.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu13061902</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Eating disorders ; Resveratrol</subject><ispartof>Nutrients, 2021-06, Vol.13 (6)</ispartof><rights>COPYRIGHT 2021 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Déchelotte, Pierre</creatorcontrib><creatorcontrib>Breton, Jonathan</creatorcontrib><creatorcontrib>Trotin-Picolo, Clémentine</creatorcontrib><creatorcontrib>Grube, Barbara</creatorcontrib><creatorcontrib>Erlenbeck, Constantin</creatorcontrib><creatorcontrib>Bothe, Gordana</creatorcontrib><creatorcontrib>Fetissov, Sergueï O</creatorcontrib><creatorcontrib>Lambert, Grégory</creatorcontrib><title>The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study</title><title>Nutrients</title><description>Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597[sup.®] (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH, reduced weight gain and adiposity in rodent models of obesity. Methods: To investigate the clinical efficacy of HA, 236 overweight subjects were included, after written informed consent, in a 12-week prospective, double-blind, randomized study. All subjects received standardized counselling for a −20% hypocaloric diet and were asked to maintain their usual physical activity. Subjects of the HA group received two capsules per day providing 100 billion bacteria per day and subjects in the Placebo (P) group received two placebo capsules. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. Intention-to-treat statistical analysis was performed using exact-Fischer, Mann-Whitney and paired-Wilcoxon tests as appropriate. Results: In the HA group, significantly more subjects (+33%) met the primary endpoint than in the P group (54.9 vs. 41.4%, p = 0.048). In the HA group, an increased feeling of fullness (p = 0.009) and a greater loss of hip circumference (p &lt; 0.001) at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower (p &lt; 0.05) in the HA compared to P group. Clinical and biological tolerance was good in both groups. Conclusions: A 12-week treatment with the probiotic strain H. alvei HA4597[sup.®] significantly improves weight loss, feeling of fullness and reduction of hip circumference in overweight subjects following moderate hypocaloric diet. These data support the use of H. alvei HA4597[sup.®] in the global management of excess weight.</description><subject>Eating disorders</subject><subject>Resveratrol</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptUNtKAzEQXURB0b74BQFfuzV7abLrW62XFlpabMEHkZLLbBtJk7LJVvSj_Ag_wG8ypT70wZlhZjicMzNMFF0muJNlJb42TZJhkpQ4PYrOUkzTmJA8Oz7oT6OWc294ZxRTkp1FP_MVoGltubJeCTTzNVMGDQcdxPQW1PUQDXp5t6Qvrtl0vr9e0XC9qe0WHHoGtVx5NLLOoSCZbKF-30Ozhr-B8A41RkKNxjZk5gENPjZWMG3rsOhOgb9Bvd1qW8Uh-tYI2Pg2Gjc6XALGB-kTM9Ku1SfINrqzDdcQ32plJJpqJoDbncrXVmuQ4fRGflxEJxXTDlp_9TyaP9zP-4N4NHkc9nujeEloHpcVZQVJCStEQoBLnlWMBIwmgqfAOMUcd7tFCRWusEgkEwUkeV6keSY45jw7j672Y5dMw0KZyoa_ibVyYtGjpFsQUuZ5YHX-YQWXsFbCGqhUwA8Ev4hFjdk</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Déchelotte, Pierre</creator><creator>Breton, Jonathan</creator><creator>Trotin-Picolo, Clémentine</creator><creator>Grube, Barbara</creator><creator>Erlenbeck, Constantin</creator><creator>Bothe, Gordana</creator><creator>Fetissov, Sergueï O</creator><creator>Lambert, Grégory</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20210601</creationdate><title>The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study</title><author>Déchelotte, Pierre ; Breton, Jonathan ; Trotin-Picolo, Clémentine ; Grube, Barbara ; Erlenbeck, Constantin ; Bothe, Gordana ; Fetissov, Sergueï O ; Lambert, Grégory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g674-9f7a8626a8c16ebdb3fa6f7a71cb2eab70b05589ef0f0c1dac8e1448243cb0bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Eating disorders</topic><topic>Resveratrol</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Déchelotte, Pierre</creatorcontrib><creatorcontrib>Breton, Jonathan</creatorcontrib><creatorcontrib>Trotin-Picolo, Clémentine</creatorcontrib><creatorcontrib>Grube, Barbara</creatorcontrib><creatorcontrib>Erlenbeck, Constantin</creatorcontrib><creatorcontrib>Bothe, Gordana</creatorcontrib><creatorcontrib>Fetissov, Sergueï O</creatorcontrib><creatorcontrib>Lambert, Grégory</creatorcontrib><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Déchelotte, Pierre</au><au>Breton, Jonathan</au><au>Trotin-Picolo, Clémentine</au><au>Grube, Barbara</au><au>Erlenbeck, Constantin</au><au>Bothe, Gordana</au><au>Fetissov, Sergueï O</au><au>Lambert, Grégory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study</atitle><jtitle>Nutrients</jtitle><date>2021-06-01</date><risdate>2021</risdate><volume>13</volume><issue>6</issue><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597[sup.®] (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH, reduced weight gain and adiposity in rodent models of obesity. Methods: To investigate the clinical efficacy of HA, 236 overweight subjects were included, after written informed consent, in a 12-week prospective, double-blind, randomized study. All subjects received standardized counselling for a −20% hypocaloric diet and were asked to maintain their usual physical activity. Subjects of the HA group received two capsules per day providing 100 billion bacteria per day and subjects in the Placebo (P) group received two placebo capsules. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. Intention-to-treat statistical analysis was performed using exact-Fischer, Mann-Whitney and paired-Wilcoxon tests as appropriate. Results: In the HA group, significantly more subjects (+33%) met the primary endpoint than in the P group (54.9 vs. 41.4%, p = 0.048). In the HA group, an increased feeling of fullness (p = 0.009) and a greater loss of hip circumference (p &lt; 0.001) at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower (p &lt; 0.05) in the HA compared to P group. Clinical and biological tolerance was good in both groups. Conclusions: A 12-week treatment with the probiotic strain H. alvei HA4597[sup.®] significantly improves weight loss, feeling of fullness and reduction of hip circumference in overweight subjects following moderate hypocaloric diet. These data support the use of H. alvei HA4597[sup.®] in the global management of excess weight.</abstract><pub>MDPI AG</pub><doi>10.3390/nu13061902</doi></addata></record>
fulltext fulltext
identifier ISSN: 2072-6643
ispartof Nutrients, 2021-06, Vol.13 (6)
issn 2072-6643
2072-6643
language eng
recordid cdi_gale_infotracmisc_A765866944
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Eating disorders
Resveratrol
title The Probiotic Strain IH. alvei/I HA4597[sup.®] Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A18%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Probiotic%20Strain%20IH.%20alvei/I%20HA4597%5Bsup.%C2%AE%5D%20Improves%20Weight%20Loss%20in%20Overweight%20Subjects%20under%20Moderate%20Hypocaloric%20Diet:%20A%20Proof-of-Concept,%20Multicenter%20Randomized,%20Double-Blind%20Placebo-Controlled%20Study&rft.jtitle=Nutrients&rft.au=D%C3%A9chelotte,%20Pierre&rft.date=2021-06-01&rft.volume=13&rft.issue=6&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu13061902&rft_dat=%3Cgale%3EA765866944%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A765866944&rfr_iscdi=true